How can a person know if the emerging corona virus "Covid-19" vaccine is effective?

Is it advisable to check antibody levels after completing the two vaccination doses?

And what is the current discussion about the AstraZeneca-Oxford vaccine against the Coronavirus?

Answers are in this report.

Writer Maria Faller - in a report published by the American Health Digest site - says that the reports received from the vaccinated individuals were divided into two parts: Some of them faced side effects after receiving the vaccine dose, such as headache, fever, fatigue and a rash at the site. Injection or near it;

Some of them did not suffer from any symptoms at all.

Many doctors say the symptoms listed are normal, and they indicate a healthy immune-boosting response in the body.

According to the Centers for Disease Control and Prevention, it is common to have no reaction after receiving a dose of the vaccine, but it is also normal to have swelling, redness, or pain at the injection site, in addition to a fever. Chills and muscle aches.

Often the side effects last only a few days, but they may prevent the person from performing their daily tasks, such as work.

According to the "Health Line" website, adverse reactions often appear after receiving the second dose of the "Pfizer-BioNTech" and "Moderna" vaccines.

 Follow directions to ensure effectiveness

In an interview with Healthline, Dr. Debra Powell emphasized that the presence or absence of adverse reactions is not a cause for concern;

Due to the difference in response from one person to another.

For both Pfizer and Moderna vaccines, the best way to ensure optimal immunity is to obtain a second dose and complete a complete vaccination.

Dr. Powell added that the first dose would improve immunity by up to 50%, while the second dose would gain the body with immunity up to 95%.

In fact, the side effects or their absence are not what determines the effectiveness of the vaccine, but rather obtaining the second dose "as close as possible to the recommended period of time", according to the US Centers for Disease Control and Prevention guidelines.

The author said that some people may resort to checking their antibody levels after completing the two vaccination doses, but the US Centers for Disease Control and Prevention advises otherwise.

It states on its website that "antibody testing is not recommended to assess immunity against SARS-CoV-2 after receiving the vaccination."

The "Washington Post" newspaper quoted - infectious disease expert Rob Murphy - that "after receiving the vaccine, many people will undergo antibody tests."

This is a desire to know the effectiveness of vaccination, but the result of the examination is almost completely independent of the effectiveness of the vaccination.

Murphy added that "many people will have a negative result in the antibody test, but this does not mean that the vaccine did not succeed."

Five things to know about the "AstraZeneca-Oxford" vaccine against Corona

We move to the "AstraZeneca-Oxford" vaccine, about which a discussion is currently underway, including the possibility of causing strokes, and delayed deliveries to countries that have requested it.

The "AstraZeneca-Oxford" vaccine is characterized by being inexpensive, and it was developed from a virus that infects "chimpanzees", but it accumulates disappointments, including doubts about serious side effects, although they are rare.

Here are 5 things to know about the vaccine:

1- It was developed based on a virus circulating in "chimpanzees"

The vaccine was developed by researchers at the University of "Oxford" in cooperation with the giant pharmaceutical company "AstraZenica", and this vaccine depends on a "viral vector", meaning that it is based on another virus, "adenoviruses" spread among "chimpanzees", Weakened and adapted to fight the emerging corona virus.

And his method of delivering genetic material to cells - and directing it to attack the "SARS-Cove-2" virus, which is the scientific name for Corona virus - has been described as a "Trojan horse."

2- A practical vaccine

One of the most prominent features of the AstraZeneca and Oxford University vaccine is that it costs a little about 2.50 euros (about $ 2.9) per dose.

And also it is easy to store;

It requires a temperature between 2 and 8 degrees Celsius, which is the temperature of normal refrigerators, and this matter facilitates pollination on a large scale, unlike the "Moderna" and "Pfizer-Biontech" vaccines, which can only be stored in the long term at very low temperatures of 20 degrees Below zero for the first vaccine, and minus 70 degrees for the second vaccine.

3- Questions about its side effects

Doubts about possible serious side effects, although rare, are increasing, after atypical blood clots have been observed in some people who have been vaccinated with AstraZeneca.

Dozens of these cases were recorded, some of which resulted in death.

The United Kingdom has reported 30 cases and 7 deaths so far, out of a total of 18.1 million doses used as of March 24, and no similar observation was reported after millions of doses of the "Pfizer-Biontech" vaccine were administered.

According to the European Medicines Agency, "no causal link (with the vaccine) has been proven," and of course the benefits of vaccination against the Corona virus always carry risks.

Some countries decided not to give this vaccine to people under a certain age as a matter of caution, such as Germany and the Netherlands (60 years), France, Canada (55 years), Sweden and Finland (65 years).

And AstraZeneca confirmed in March that there was "no evidence of high risk".

4- Effectiveness

According to AstraZeneca, the effectiveness of the vaccine is 70% (compared to more than 90% for Pfizer-Biontec and Moderna), a percentage confirmed by the specialized magazine "The Lancet".

Preliminary results showed a difference in effectiveness according to the dose used, as a result of a mistake in determining the dose, which sparked criticism, prompting the company to conduct additional studies.

Skepticism also emerged in Europe about its effectiveness in people over the age of 65, due to a lack of data, before new studies showed that it was safe.

The US health authorities criticized the company after it received "old" data about its clinical trials. As a result, the effectiveness of the vaccine was reduced to 76% against non-symptomatic forms of infection, after it was 79% at the beginning.

British studies - conducted under realistic conditions in Scotland and England - showed that the vaccine provides important hospitalization protection (94% after 4 weeks of study in Scotland).

5- Delayed deliveries

According to AstraZeneca, the vaccine was licensed in more than 70 countries until mid-March, and Britain was the first country to approve its use and requested 100 million doses of it.

In the European Union, the company has been criticized for delaying delivery of a shipment that it had destined for the United Kingdom.

In light of the weak deliveries - compared to what was stated in the agreement - the European Commission decided to tighten controls on exports of anti-corona vaccines outside the countries of the European Union.

This caused a sharp quarrel between Brussels and London, which pledged to settle the dispute through negotiation.